What diseases are avatrombopag tablets mainly used to treat?

Avatrombopag tablets are an oral thrombopoietin receptor agonist mainly used to treat thrombocytopenia. It promotes platelet production by stimulating the proliferation and differentiation of megakaryocytes in the bone marrow. Unlike traditional blood transfusions or hormone therapy, avatrombopag can mildly and continuously increase platelet levels and reduce the risk of bleeding. It is one of the important drugs for the treatment of patients with chronic thrombocytopenia.

Currently, the most common indication for avatrombopag is the management of thrombocytopenia in patients with chronic liver disease before undergoing elective procedures (such as biopsy, surgery, etc.). Such patients have low platelet levels and high surgical risks. The use of avatrombopag can significantly increase the number of platelets, thereby reducing the possibility of intraoperative and postoperative bleeding and improving the safety of treatment. In addition, it is also suitable for certain adult patients with chronic immune thrombocytopenia (ITP), especially those who have an inadequate response to steroid or immunosuppressive therapy.

In the treatment of chronic immune thrombocytopenia, avatrombopag, as a non-immunosuppressive treatment modality, provides patients with a new option. Studies have shown that the drug can take effect within about a week, significantly increase platelet levels, and most patients can maintain relatively stable platelet numbers. Compared with traditional treatment, it has relatively few side effects, especially does not suppress the body's immune system, so it is safer in long-term treatment.

Overall, avatrombopag is an efficient and relatively safe platelet production promoter, suitable for patients with thrombocytopenia caused by chronic liver disease or immune diseases. Its advantages of oral convenience, rapid onset of action, and long maintenance time make it recognized and recommended by more and more doctors in clinical practice. With the deepening of research, it is expected to play a role in more blood system diseases in the future and further improve the quality of life of patients.

Reference materials:https://go.drugbank.com/drugs/DB11995